Roche Expands its HCV Pipeline with Anadys Pharmaceuticals Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 11 (Table of Contents)
Published: 2 Nov-2011
DOI: 10.3833/pdr.v2011.i11.1594 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Roche has agreed to acquire Anadys Pharmaceuticals and its portfolio of two hepatitis C virus (HCV) drug candidates for US$3...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS